Diagnostic Value of Ultrasonography Combined with Serum IL-1β And CYFRA21-1 in Ovarian Cancer
-
摘要:
目的 探究超声联合血清白细胞介素-1β(interleukin-1β,IL-1β)、C角蛋白19片段抗原21-1(cytokeratin 19 fragment antigen 21-1,CYFRA21-1)对卵巢癌的诊断价值。 方法 于2020年7月至2023年7月选取沧州中西医结合医院收治的卵巢肿瘤患者250例,经病理检测确诊为卵巢癌的患者114例即为卵巢癌组,从136例良性肿瘤患者中随机选择114例卵巢良性病变患者即为对照组。采用彩色超声诊断仪对所有研究对象进行诊断。采用酶联免疫吸附(enzyme linked immunosorbent assay,ELISA)法检测血清中IL-1β、CYFRA21-1水平。Kappa检验分析诊断方法与手术病理结果的一致性。多因素Logistic回归分析卵巢癌发生影响因素。受试者工作特征(receiver operating characteristic,ROC)曲线分析超声联合血清IL-1β、CYFRA21-1对卵巢癌的诊断价值。 结果 卵巢癌组患者血清中IL-1β、CYFRA21-1水平与对照组相比显著升高(P < 0.05)。与透明细胞癌相比,粘液性腺癌和浆液性腺癌患者血清中IL-1β、CYFRA21-1水平依次显著升高(P < 0.05)。卵巢癌患者血清中IL-1β、CYFRA21-1水平在Ⅰ期<Ⅱ期<Ⅲ期<Ⅳ期(P < 0.05)。血清IL-1β、CYFRA21-1水平升高是卵巢癌发生的危险因素(P < 0.05)。超声联合血清IL-1β、CYFRA21-1对卵巢癌诊断的曲线下面积(area under the curve,AUC)显著高于单一指标诊断的AUC值(Z超声~超声+IL-1β+CYFRA21-1=3.782,P < 0.001;ZIL-1β~超声+IL-1β+CYFRA21-1=4.046,P < 0.001;ZCYFRA21-1~超声+IL-1β+CYFRA21-1=7.279,P < 0.001)。以病理检查结果为依据,联合诊断的一致性(Kappa值=0.789)高于超声(Kappa值=0.658)单独诊断。 结论 超声联合血清IL-1β、CYFRA21-1对卵巢癌的诊断效能较高,有一定的临床意义。 -
关键词:
- 超声 /
- 白细胞介素-1β /
- C角蛋白19片段抗原21-1 /
- 卵巢癌 /
- 诊断
Abstract:Objective To explore the diagnostic value of ultrasound combined with serum interleukin-1β (IL-1β) and cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) in ovarian cancer. Methods From July 2020 to July 2023, 250 patients with ovarian tumors admitted to Cangzhou Integrated Chinese and Western Medicine Hospital were enrolled. Among them, 114 patients confirmed as having ovarian cancer by pathological examination comprised the ovarian cancer group. Additionally, 114 patients were randomly selected from the remaining 136 patients with benign tumors to form the control group. All study subjects underwent diagnosis using color ultrasound diagnostic equipment. Serum levels of IL-1β and CYFRA21-1 were detected using the enzyme linked immunosorbent assay (ELISA) method. Kappa test was used to analyze the consistency between diagnostic methods and surgical pathological results. Multivariate logistic regression analysis was performed to identify risk factors for ovarian cancer occurrence. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic value of ultrasound combined with serum IL-1β and CYFRA21-1 for ovarian cancer. Results Serum levels of IL-1β and CYFRA21-1 in the ovarian cancer group were significantly elevated compared to the control group (P < 0.05). Compared with clear cell carcinoma, serum levels of IL-1β and CYFRA21-1 in patients with mucinous adenocarcinoma and serous adenocarcinoma were significantly elevated (P < 0.05). Serum levels of IL-1β and CYFRA21-1 in ovarian cancer patients showed a progressive increase across stages I<stage II<stage III<stage IV (P < 0.05). Elevated serum levels of IL-1 β and CYFRA21-1 were risk factors for ovarian cancer (P < 0.05). The area under the curve (AUC) for the combined ultrasound with serum IL-1β and CYFRA21-1 in diagnosing ovarian cancer was significantly higher than the AUC values of single-indicator diagnosis (Zultrasound~ultrasound+IL-1β+CYFRA21-1=3.782, P < 0.001; ZIL-1β~ultrasound+IL-1β+CYFRA21-1=4.046, P < 0.001; ZCYFRA21-1~ultrasound+IL-1β+CYFRA21-1=7.279, P < 0.001). Based on pathological examination results, the consistency of combined diagnosis (Kappa value=0.789) was higher than ultrasound alone (Kappa value=0.658). Conclusion : The combined diagnostic approach of ultrasound with serum IL-1β and CYFRA21-1 demonstrates high diagnostic efficacy for ovarian cancer and has certain clinical significance. -
Key words:
- Ultrasound /
- Interleukin-1β /
- Cytokeratin 19 fragment antigen 21-1 /
- Ovarian cancer /
- Diagnosis
-
表 1 一般资料比较
Table 1. Comparison of general characteristics
组别 n 年龄(岁) 体质量指数(kg/m2) 高血压 糖尿病 吸烟史 饮酒史 卵巢癌组 114 58.65 ± 6.14 21.72 ± 3.18 21(18.41) 15(13.16) 22(19.30) 34(29.82) 对照组 114 58.70 ± 6.12 21.63 ± 2.95 18(15.79) 13(11.40) 20(17.54) 32(28.07) t/χ2 - 0.062 0.222 0.278 0.163 0.117 0.085 P - 0.951 0.825 0.598 0.687 0.733 0.770 表 2 两组血清IL-1β、CYFRA21-1、CA125、HE4水平比较
Table 2. Comparison of serum IL-1 β,CYFRA21-1,CA125,and HE4 levels between two groups
组别 n IL-1β(ng/mL) CYFRA21-1(ng/mL) CA125(U/mL) HE4(pmol/L) 卵巢癌组 114 13.71 ± 1.53 27.36 ± 3.02 47.12 ± 6.95 115.86 ± 20.37 对照组 114 11.84 ± 1.50 23.56 ± 2.95 26.12 ± 3.68 56.78 ± 9.74 t - 9.318 9.611 28.511 27.938 P - <0.001* <0.001* <0.001* <0.001* *P < 0.05。 表 3 不同病理分型患者血清中IL-1β、CYFRA21-1水平比较
Table 3. Comparison of serum IL-1 β and CYFRA21-1 levels in patients with different pathological subtypes
组别 n IL-1β(ng/mL) CYFRA21-1(ng/mL) 浆液性腺癌 58 14.35 ± 1.53ab 28.58 ± 3.01ab 粘液性腺癌 41 13.42 ± 1.52a 26.85 ± 3.03a 透明细胞癌 15 12.05 ± 1.52 24.01 ± 3.02 F - 14.733 14.560 P - <0.001* <0.001* 与透明细胞癌相比,aP < 0.05;与粘液性腺癌相比,bP < 0.05;*P < 0.05。 表 4 不同分期患者血清IL-1β、CYFRA21-1水平比较
Table 4. Comparison of serum IL-1 β and CYFRA21-1 levels in patients of different stages
组别 n IL-1β(ng/mL) CYFRA21-1(ng/mL) Ⅰ期 27 12.06 ± 1.35 23.89 ± 2.81 Ⅱ期 25 13.15 ± 1.41a 26.32 ± 2.95a Ⅲ期 33 14.33 ± 1.49ab 28.64 ± 3.02ab Ⅳ期 29 15.02 ± 1.51abc 30.03 ± 3.06abc F - 22.926 23.213 P - <0.001* <0.001* 与Ⅰ期相比,aP < 0.05;与Ⅱ期相比,bP < 0.05;与Ⅲ期相比,cP < 0.05;*P < 0.05。 表 5 影响卵巢癌发生的多因素Logistic回归分析
Table 5. Multivariate logistic regression analysis of factors affecting the occurrence of ovarian cancer
影响因素 B SE Waldχ2 OR 95%CI P 超声 0.407 0.182 4.996 1.502 1.051~2.146 0.025* IL-1β 0.667 0.217 9.457 1.949 1.274~2.982 0.002* CYFRA21-1 0.301 0.1114 6.964 1.351 1.080~1.689 0.008* *P < 0.05。 表 6 超声与手术病理诊断卵巢癌良恶性一致性(n)
Table 6. Consistency between Ultrasound and Surgical Pathology Diagnosis of Benign and Malignant Ovarian Cancer (n)
超声 手术病理结果 恶性(n=114) 良性(n=114) 恶性(n = 103) 89 14 良性(n = 125) 25 100 Kappa 0.658 P <0.001* *P < 0.05。 表 7 超声联合血清IL-1β和CYFRA21-1与手术病理诊断卵巢癌良恶性一致性(n)
Table 7. Consistency of ultrasound combined with serum IL-1 β and CYFRA21-1 with surgical pathological diagnosis of benign and malignant ovarian cancer (n)
超声联合血清IL-1β和
CYFRA21-1手术病理结果 恶性(n=114) 良性(n=114) 恶性(n = 128) 109 19 良性(n = 100) 5 95 Kappa 0.789 P <0.001* *P < 0.05。 -
[1] 蔡晶, 王泽华. 妇科恶性肿瘤筛查和早期诊断中的挑战[J]. 中国医师杂志, 2023, 25(5): 641-643. doi: 10.3760/cma.j.cn431274-20230330-00423 [2] 刘欣, 王登凤, 张国楠, 等. 血清白蛋白对晚期卵巢癌患者治疗方式选择的评估价值[J]. 肿瘤预防与治疗, 2021, 34(5): 414-419. doi: 10.3969/j.issn.1674-0904.2021.05.006 [3] 张红岩. 拟线粒体促凋亡多肽N7在人卵巢癌细胞对顺铂增敏作用的研究[D]. 郑州: 郑州大学, 2013. [4] 吴淑霞, 宋文成, 李涛, 等. 经阴道超声用于术前诊断原发性卵巢癌盆底腹膜转移的可行性分析[J]. 实用癌症杂志, 2017, 32(2): 330-331. doi: 10.3969/j.issn.1001-5930.2017.02.048 [5] 刘超敏, 王涛. 卵巢癌的生物标志物CA125和HE4研究进展[J]. 甘肃医药, 2019, 38(5): 395-397. doi: 10.15975/j.cnki.gsyy.2019.05.004 [6] 王訸, 刘甜, 陈意, 等. 超声内镜引导下细针穿刺液基细胞学在消化系统疾病病理诊断中的应用[J]. 诊断病理学杂志, 2021, 28(4): 307-310. [7] 丁竟成, 黄磊, 李婷, 等. 白细胞介素-1β、人附睾蛋白4及Sp1对上皮性卵巢癌的诊断及预后预测价值分析[J]. 癌症进展, 2021, 19(5): 487-490, 540. doi: 10.11877/j.issn.1672-1535.2021.19.05.14 [8] 刘文楼, 王红梅, 秦晓冰, 等. 血清HE4、VEGF、CYFRA21-1联合检测在非小细胞肺癌诊断中的意义及其与临床病理特征的关系[J]. 徐州医科大学学报, 2020, 40(9): 625-630. doi: 10.3969/j.issn.2096-3882.2020.09.001 [9] 徐燕, 王英, 孙勃, 等. 上皮性卵巢癌患者术前NLR、PLR、CEA、Cyfra21-1、CA125水平变化及其临床意义[J]. 实用癌症杂志, 2022, 37(7): 1080-1084. doi: 10.3969/j.issn.1001-5930.2022.07.008 [10] 王黎伟, 王志芬, 孔丽茹, 等. 超声造影联合血清基质细胞衍生因子-1和磷酸化应激诱导蛋白1检测对卵巢癌的诊断价值[J]. 新乡医学院学报, 2021, 38(5): 481-484. doi: 10.7683/xxyxyxb.2021.05.018 [11] 唐英, 李均, 胡辉权, 等. 血小板与淋巴细胞比值对卵巢癌患者国际妇产科联盟临床分期的预测价值[J/OL]. 中华妇幼临床医学杂志(电子版), 2019, 15(3): 268-274. [12] 张爱臣, 佟玲玲. 卵巢癌的诊治进展[J]. 中国计划生育和妇产科, 2013, 5(1): 5-8. [13] 刘婧, 陈秋月, 吕国荣. 超声国际卵巢肿瘤研究组简单法则与妇科影像报告与数据系统分类诊断卵巢肿瘤的比较[J]. 中国医学影像技术, 2017, 33(5): 739-742. doi: 10.13929/j.1003-3289.201610141 [14] 曾丽. AKT2通过PKM2调控卵巢癌细胞增殖作用的研究[D]. 福州: 福建医科大学, 2015. [15] Zhang H, Zhang X M, Zong D D, et al. miR-34a-5p up-regulates the IL-1β/COX2/PGE2 inflammation pathway and induces the release of CGRP via inhibition of SIRT1 in rat trigeminal ganglion neurons[J]. FEBS Open Bio, 2021, 11(1): 300-311. doi: 10.1002/2211-5463.13027 [16] Gowda P, Lathoria K, Sharma S, et al. Rewiring of lactate–interleukin-1β autoregulatory loop with clock-Bmal1: A feed-forward circuit in glioma[J]. Mol Cell Biol, 2021, 41(9): e00449-e00420. [17] 张萌, 张向东, 夏永欣, 等. 血清B淋巴细胞瘤-2基因、细胞角蛋白19的可溶性片段21-1表达与晚期食管癌放化疗患者预后的相关性[J]. 中国卫生检验杂志, 2022, 32(23): 2883-2887, 2891. [18] Dal Bello M G, Filiberti R A, Alama A, et al. The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients[J]. J Transl Med, 2019, 17(1): 74. doi: 10.1186/s12967-019-1828-0 [19] Cao X, Zhang L, Feng G R, et al. Preoperative Cyfra21-1 and SCC-Ag serum titers predict survival in patients with stage II esophageal squamous cell carcinoma[J]. J Transl Med, 2012, 10: 197. doi: 10.1186/1479-5876-10-197 [20] Jin C, Yang M, Han X, et al. Evaluation of the value of preoperative CYFRA21-1 in the diagnosis and prognosis of epithelial ovarian cancer in conjunction with CA125[J]. J Ovarian Res, 2019, 12(1): 114. doi: 10.1186/s13048-019-0587-0 [21] 邢丹, 郭佳, 陈仪. 纤维蛋白原、糖类抗原125、人附睾蛋白4联合检测对早期卵巢癌的诊断价值[J]. 癌症进展, 2024, 22(9): 991-994. doi: 10.11877/j.issn.1672-1535.2024.22.09.13 -
下载: